GRI

GRI Bio Inc. (GRI) | Rumor.io

GRI Bio

GRI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,695

Bullish sentiment (50-day avg)91%

Price to earnings ratio0.04

Market capitalization4.6M

Earnings per share-2.83

Dividend yield (TTM)97.3%

Revenue (annual)0

Net income (annual)-12M

Social

What share of all stock conversation is about GRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% new	0% +0	0% 0

Sep 8

GRI Bio presented new Phase 2a data at ERS 2026, defining the mechanism of action for GRI-0621 in idiopathic pulmonary fibrosis (IPF) across nine mechanistic pillars.
The U.S. IPF market opportunity is projected to be a key metric, with GRI Bio presenting forward-looking statements about product development, commercialization strategy, and potential market opportunities.
GRI Bio stock price surged 25% following the presentation of Phase 2a IPF data at ERS 2026, with investors taking note of the significant increase.

Generated by AI

Sentiment

Of the messages about GRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	98.1% +38.1	74.33% -9.76
Bearish	0%	0%	1.9% -38.1	25.67% +9.76

Bullish· Aug 11

The chart for $GRI is solid, and the company's strategy of diluting with the trend is a good sign, with a target price of $3-$4.
The stock is showing a deep bullish pattern, and the volume is increasing, which could lead to a significant price increase.
$GRI has a strong potential for a massive run-up, with a predicted price of $6.00 by Friday and a possible range of $21.00 to $32.00 in the near future.

Bearish· Aug 12

The company is facing severe dilution risk due to its high burn rate of $3.69 million per quarter and limited cash runway, with only 4.5 months remaining before it needs to raise capital.
The company has tapped into an ATM of $250 million to dilute shareholders during any sudden volume spikes, and has also positioned a $60 million ATM vehicle to further dilute owners in the future.
The company's warrants and historical S-1 offerings have expanded its fully diluted share count to over 30 million, which could lead to a massive influx of shares into the market if warrants are exercised, potentially putting a ceiling on the stock price.

Generated by AI

Topics

Of the messages about GRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	80%	83.33%	60.23%	26.81%
Technical Analysis	20%	16.67%	3.51%	34.26%
Analysts	0%	0%	18.13%	19.8%
Macro	0%	0%	18.13%	18.97%
Controversies	0%	0%	0%	0.17%
Earnings	0%	0%	0%	0%

Announcements· Apr 1

GRI Bio reports encouraging interim 2-week safety results from its ongoing Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis (IPF).
GRI Bio announces the pricing of a $5.0 million public offering, issuing 1,388,888 shares of common stock and Series E-1 warrants to purchase up to 1,388,888 shares of common stock.
GRI Bio's Phase 2a study of GRI-0621 in IPF shows positive interim 2-week safety data, a small molecule RAR-βγ dual agonist for the treatment of IPF.

Technical Analysis· Oct 21

The 50 Day Moving Average on GRI's Daily Chart has been broken, which may be contributing to the stock's current hype.
The MACD is crossing back over and the RSI is low, suggesting a potential reversal in GRI's trend.
GRI's chart is showing signs of coiling, with a potential base formation, and may be primed for a new breakout to new levels.

Generated by AI

Community

Of the messages about GRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.33%	85.71%	69.67%	40.43%
Newcomers	16.67%	14.29%	30.33%	59.57%

Regulars· Sep 4

The company GRI Bio has announced that three abstracts and an oral presentation will be presented at the 2026 European Respiratory Society Congress, highlighting data from the Phase 2a GRI-0621-IPF-02 study for the treatment of idiopathic pulmonary fibrosis.
Regulars are discussing the potential for the stock to reach $3, with some mentioning the possibility of a 3$ break and considering trend before taking gains.
The stock is experiencing buying interest, with several regulars mentioning lots of buying and some taking positions in anticipation of a potential 3$ push.

Newcomers· Sep 4

New investors are hoping to buy GRI at $2.55 support, with some feeling close to selling.
Users are discussing GRI's upcoming presentations, which are scheduled for Sunday, and are considering a potential R/S (reverse split) or offering.
Investors are concerned about GRI's history of toxic dilution and financing, and are warning others to be cautious, with one user labeling the company a "crap company".

Generated by AI

News

GRI Bio executives to present at IPF Summit this week

1d agoInvesting.com

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

15d agoYahoo Finance

Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621

21d agoInvesting.com

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection Signals observed from at least two independent measurement modalities, including RNA sequencing, serum extracellular matrix biomarkers, spectral flow cytometry and clinical readouts, supported each of the nine pre-specified mechanistic pillars, defining a rep

22d agoYahoo Finance

12 Health Care Stocks Moving In Thursday's Intraday Session

26d agoBenzinga

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available here LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a "Why Now" video webcast. During the webcast, Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio, discusses the Company's differentiated approach to treating idiopathic pulmonary fibrosis (IPF) through GRI-0621

1mo agoYahoo Finance

Also Discussed

Investors talking about GRI also mention

#	Name	Attention
1	Expion360 Inc.XPON	0%0
2	MicroAlgo Inc.MLGO	0%new
3	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
4	Allarity Therapeutics Inc.ALLR	0%-0.01
5	SU Group Holdings LimitedSUGP	0%+0
6	Jiade Ltd. Class A Ordinary SharesJDZG	0%0
7	Carmell CorporationCTCX	0%0
8	IVP - Inspire Veterinary Partners, Inc.	——
9	ZCAR - Zoomcar Holdings, Inc.	——
10	Tenon Medical, Inc.TNON	0%new

GRI Bio Inc.

Healthcare
Biotechnology

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression. Its lead program, GRI-0621, is an oral candidate being developed for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. The company is also advancing GRI-0803 for autoimmune disorders, alongside additional early-stage programs and a proprietary library of compounds that support its research pipeline. Based in La Jolla, California, GRI Bio Inc. operates in the biotechnology sector and concentrates on translating immune-system biology into drug candidates for unmet medical needs in specialty disease areas.

Website

Location

2223 Avenida de la Playa

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about GRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% new	0% +0	0% 0

Sep 8

GRI Bio presented new Phase 2a data at ERS 2026, defining the mechanism of action for GRI-0621 in idiopathic pulmonary fibrosis (IPF) across nine mechanistic pillars.
The U.S. IPF market opportunity is projected to be a key metric, with GRI Bio presenting forward-looking statements about product development, commercialization strategy, and potential market opportunities.
GRI Bio stock price surged 25% following the presentation of Phase 2a IPF data at ERS 2026, with investors taking note of the significant increase.

Generated by AI

Sentiment

Of the messages about GRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	98.1% +38.1	74.33% -9.76
Bearish	0%	0%	1.9% -38.1	25.67% +9.76

Bullish· Aug 11

The chart for $GRI is solid, and the company's strategy of diluting with the trend is a good sign, with a target price of $3-$4.
The stock is showing a deep bullish pattern, and the volume is increasing, which could lead to a significant price increase.
$GRI has a strong potential for a massive run-up, with a predicted price of $6.00 by Friday and a possible range of $21.00 to $32.00 in the near future.

Bearish· Aug 12

The company is facing severe dilution risk due to its high burn rate of $3.69 million per quarter and limited cash runway, with only 4.5 months remaining before it needs to raise capital.
The company has tapped into an ATM of $250 million to dilute shareholders during any sudden volume spikes, and has also positioned a $60 million ATM vehicle to further dilute owners in the future.
The company's warrants and historical S-1 offerings have expanded its fully diluted share count to over 30 million, which could lead to a massive influx of shares into the market if warrants are exercised, potentially putting a ceiling on the stock price.

Generated by AI

Topics

Of the messages about GRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	80%	83.33%	60.23%	26.81%
Technical Analysis	20%	16.67%	3.51%	34.26%
Analysts	0%	0%	18.13%	19.8%
Macro	0%	0%	18.13%	18.97%
Controversies	0%	0%	0%	0.17%
Earnings	0%	0%	0%	0%

Announcements· Apr 1

GRI Bio reports encouraging interim 2-week safety results from its ongoing Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis (IPF).
GRI Bio announces the pricing of a $5.0 million public offering, issuing 1,388,888 shares of common stock and Series E-1 warrants to purchase up to 1,388,888 shares of common stock.
GRI Bio's Phase 2a study of GRI-0621 in IPF shows positive interim 2-week safety data, a small molecule RAR-βγ dual agonist for the treatment of IPF.

Technical Analysis· Oct 21

The 50 Day Moving Average on GRI's Daily Chart has been broken, which may be contributing to the stock's current hype.
The MACD is crossing back over and the RSI is low, suggesting a potential reversal in GRI's trend.
GRI's chart is showing signs of coiling, with a potential base formation, and may be primed for a new breakout to new levels.

Generated by AI

Community

Of the messages about GRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.33%	85.71%	69.67%	40.43%
Newcomers	16.67%	14.29%	30.33%	59.57%

Regulars· Sep 4

The company GRI Bio has announced that three abstracts and an oral presentation will be presented at the 2026 European Respiratory Society Congress, highlighting data from the Phase 2a GRI-0621-IPF-02 study for the treatment of idiopathic pulmonary fibrosis.
Regulars are discussing the potential for the stock to reach $3, with some mentioning the possibility of a 3$ break and considering trend before taking gains.
The stock is experiencing buying interest, with several regulars mentioning lots of buying and some taking positions in anticipation of a potential 3$ push.

Newcomers· Sep 4

New investors are hoping to buy GRI at $2.55 support, with some feeling close to selling.
Users are discussing GRI's upcoming presentations, which are scheduled for Sunday, and are considering a potential R/S (reverse split) or offering.
Investors are concerned about GRI's history of toxic dilution and financing, and are warning others to be cautious, with one user labeling the company a "crap company".

Generated by AI

GRI Bio

Social

Sep 8

Bullish· Aug 11

Bearish· Aug 12

Announcements· Apr 1

Technical Analysis· Oct 21

Regulars· Sep 4

Newcomers· Sep 4

GRI Bio executives to present at IPF Summit this week

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

12 Health Care Stocks Moving In Thursday's Intraday Session

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Also Discussed

GRI Bio Inc.

Company Information

Location

GRI Bio executives to present at IPF Summit this week

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

Gri Bio reports Phase 2a data for IPF drug candidate GRI-0621

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

12 Health Care Stocks Moving In Thursday's Intraday Session

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Also Discussed

Social

Sep 8

Bullish· Aug 11

Bearish· Aug 12

Announcements· Apr 1

Technical Analysis· Oct 21

Regulars· Sep 4

Newcomers· Sep 4